# Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

> **NCT00126724** · PHASE1,PHASE2 · COMPLETED · sponsor: **Targeted Genetics Corporation** · enrollment: 120 (estimated)

## Conditions studied

- Arthritis, Rheumatoid
- Arthritis, Psoriatic
- Ankylosing Spondylitis

## Interventions

- **GENETIC:** tgAAC94 gene therapy vector
- **GENETIC:** tgAAC94 gene therapy vector
- **GENETIC:** tgAAC94 placebo
- **GENETIC:** tgAAC94 gene therapy vector
- **GENETIC:** tgAAC94 gene therapy vector
- **GENETIC:** tgAAC94 gene therapy vector
- **GENETIC:** tgAAC94 gene therapy vector

## Key facts

- **NCT ID:** NCT00126724
- **Lead sponsor:** Targeted Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-10
- **Final completion:** 2009-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2009-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126724, "Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00126724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*